Uticaj EGFR mutacijskog statusa na klinički tok bolesti u pacijenata sa adenokarcinomom pluća
Molecular pathology of lung adenocarcinoma, it is probably better defined as compared to other tumor types, due to its frequency, and surgical accessibility of its success in the identification of clinically important mutations in this type of cancer. EGFR (eng. Epidermal Growth Factor Receptor) mutations have been clinically most relevant mutations in lung cell carcinoma, as well as significant predictors for the therapy target chemotherapeutics. The transmembrane glycoprotein from the group of epidermal growth factor receptor is present in 10% to 15% of cases of advanced non-small cell lung cancer. The study included 29 patients in the period from Маѕ 2012 to December 2016 in the Department of Pulmonary Diseases University Clinical Centre RS implemented diagnostic and therapeutic treatment of NSCLC. All patients cytology and/or histologically confirmed adenocarcinoma of the lung, and in the Department of Pathology, University Clinical Centre RS spent additional molecular testing of existing material. The study confirms the dominance of the cited literature were adenocarcinomas and more frequent incidence in the female population and in the category of nonsmokers. The study shows that the mean duration as well as the median survival longer than one year. Kontakt osoba: Lora Novaković Lacković Original Research Respiratio